SS-31 vs Tesamorelin
Updated July 27, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of SS-31 and Tesamorelin (also searched as Tesamorelin vs SS-31) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
SS-31 centers on inflammation, while Tesamorelin leans toward metabolic. On indexed research, SS-31 is ahead (SS-31: 19 studies, Human evidence; Tesamorelin: 10, Human clinical). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •SS-31 is strongest for inflammation; Tesamorelin for metabolic.
- •Evidence: SS-31 Human evidence (19 studies) vs Tesamorelin Human clinical (10).
- •Check the FDA-approval status chips above before assuming a legal use pathway.
Effect profiles, overlaid
At a glance
Mitochondrial-Targeted Peptide | Cardiolipin Protector
GHRH Analog | Visceral Fat Reduction
SS-31 vs Tesamorelin: side-by-side
| Metric | SS-31 | Tesamorelin |
|---|---|---|
| Class | Longevity | GH |
| Regulatory status | Research use only | FDA-approved |
| Evidence grade | Human evidence | Human clinical |
| Studies indexed | 19 | 10 |
| Research level | Well Studied | FDA Approved |
| Strongest effect | Inflammation & immune | Metabolic & appetite |
| Healing & recovery | 3.0▲ | 1.0 |
| Muscle & body comp | 2.0▲ | 2.0▲ |
| Metabolic & appetite | 4.0▲ | 4.0▲ |
| Neuro & mood | 3.0▲ | 1.0 |
| Sleep & circadian | 1.0▲ | 0.0 |
| Inflammation & immune | 4.0▲ | 2.0 |
| Skin & aesthetics | 0.0 | 3.0▲ |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | SS-31 | Tesamorelin |
|---|---|---|
| Mechanism | Targets inner mitochondrial membrane to enhance function and reduce ROS | GHRH analog |
| Route | Subcutaneous injection | Subcutaneous injection |
| Half-life | — | ~26–38 min |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is SS-31?
### Summary SS-31, also known as Elamipretide, is a peptide that has garnered attention for its potential role in mitochondrial protection and its implications in various health conditions, particularly those involving oxidative stress and mitochondrial dysfunction.
Full SS-31 profile, mechanism & studies →What is Tesamorelin?
### Tesamorelin Summary Tesamorelin is a synthetic peptide that functions as a growth hormone-releasing hormone (GHRH) analog, primarily investigated for its potential to reduce visceral fat in individuals with HIV-associated lipodystrophy. Its role in metabolic health and body composition continues to be explored in various clinical contexts.
Full Tesamorelin profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | SS-31 | 3.0/5 effect signal |
| Muscle | Even | Both ~2.0/5 |
| Metabolic | Even | Both ~4.0/5 |
| Neuro | SS-31 | 3.0/5 effect signal |
| Sleep | SS-31 | 1.0/5 effect signal |
| Inflammation | SS-31 | 4.0/5 effect signal |
| Skin | Tesamorelin | 3.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack SS-31 and Tesamorelin?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because at least one is a research-use compound, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
SS-31 vs Tesamorelin: side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
SS-31 has 19 approved studies indexed (Human evidence), and Tesamorelin has 10 (Human clinical). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is SS-31 or Tesamorelin better?
It depends on your goal. SS-31 is strongest for inflammation; Tesamorelin for metabolic. SS-31 has more indexed studies (19). See the goal-by-goal breakdown above.
Is SS-31 or Tesamorelin better for weight loss?
They score similarly on the metabolic/appetite axis in the community data.
Is SS-31 or Tesamorelin better for muscle?
Both land close on the muscle & body-composition axis.
Which has more research, SS-31 or Tesamorelin?
SS-31 has 19 approved studies indexed (Human evidence); Tesamorelin has 10 (Human clinical). Higher counts mean more to read, not proven superiority.
Can you stack SS-31 and Tesamorelin?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of SS-31 vs Tesamorelin?
SS-31: no community-reported effects logged yet. Tesamorelin: none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is SS-31 or Tesamorelin FDA-approved?
SS-31 is a research-use compound and is not FDA-approved. Tesamorelin is FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is Tesamorelin better than SS-31?
For metabolic, Tesamorelin has the edge; for inflammation, SS-31 does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Approval status varies (see the chips at the top). FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 27, 2026.